AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

bioAffinity Technologies ... (BIAF)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.85

0.01 (1.19%)

At close: Feb 20, 2025, 3:59 PM

0.82

-3.34%

After-hours: Feb 20, 2025, 04:18 PM EST

undefined% (undefined)

Bid	0.82
Market Cap	13.22M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.8
PE Ratio (ttm)	-1.06
Forward PE	n/a
Analyst	Buy

Ask	0.88
Volume	53,891
Avg. Volume (20D)	177,918
Open	0.79
Previous Close	0.84
Day's Range	0.78 - 0.85
52-Week Range	0.57 - 3.62
Beta	undefined

About BIAF

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas....

[Show more]

Industry Medical - Diagnostics & Research

Sector Healthcare

IPO Date Sep 1, 2022

Employees 75

Stock Exchange NASDAQ

Ticker Symbol BIAF

Website https://www.bioaffinitytech.com

Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for BIAF stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 607.30% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

bioAffinity Technologies Inc. is scheduled to release its earnings on Mar 31, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 months ago

-33.8%

bioAffinity Technologies shares are trading lower ... Unlock content with Pro Subscription

6 months ago

-27.31%

bioAffinity Technologies shares are trading lower following the pricing of a registered direct offering and concurrent private placement.

News

2 weeks ago · zacks.com

Zacks Initiates Coverage of bioAffinity With Neutral Recommendation

Discover why Zacks rates bioAffinity as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore BIAF's promising growth prospects and financial health amid market challeng...

2 months ago · businesswire.com

Join bioAffinity Technologies' Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies President and CEO Maria Zannes will be featured on RedChip Companies' investor webinar on Thursday, Dec. 19.